Is Clarus Therapeutics Holdings Inc (CRXT) a Good Choice in Drug Manufacturers

Is Clarus Therapeutics Holdings Inc (CRXT) a Good Choice in Drug Manufacturers - General Wednesday?

Wednesday, May 25, 2022 10:54 AM | InvestorsObserver Analysts

Mentioned in this article

Is Clarus Therapeutics Holdings Inc (CRXT) a Good Choice in Drug Manufacturers - General Wednesday?

A rating of 30 puts Clarus Therapeutics Holdings Inc (CRXT) near the bottom of the Drug Manufacturers - General industry according to InvestorsObserver. Clarus Therapeutics Holdings Inc's score of 30 means it scores higher than 30% of stocks in the industry. Clarus Therapeutics Holdings Inc also received an overall rating of 47, putting it above 47% of all stocks. Drug Manufacturers - General is ranked 16 out of the 148 industries.

CRXT has an Overall Score of 47. Find out what this means to you and get the rest of the rankings on CRXT!

See Full CRXT Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 47 means the stock is more attractive than 47 percent of stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Clarus Therapeutics Holdings Inc Stock Today?

Clarus Therapeutics Holdings Inc (CRXT) stock is lower by -8.51% while the S&P 500 has gained 0.65% as of 10:53 AM on Wednesday, May 25. CRXT has fallen -$0.03 from the previous closing price of $0.39 on volume of 1,775,654 shares. Over the past year the S&P 500 is down -5.28% while CRXT has fallen -96.52%. CRXT lost -$1.67 per share the over the last 12 months. Click Here to get the full Stock Report for Clarus Therapeutics Holdings Inc stock.